Advanced Biomed Inc. Common Stock (ADVB)

FairStock Score: 82/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earning power and a margin of safety. Advanced Biomed is a 31-employee Taiwan-based developer of microfluidic biochips for precision oncology. In the fiscal year ended 2026-06-30, it reported revenue of just $127,637 yet net income of $6.7M and diluted EPS of $5.33. That follows a net loss of $3.3M in the fiscal year ended 2025-06-30 and $2.8M in the fiscal year ended 2024-06-30, so the Lynch category is TURNAROUND. But the revenue line is almost nonexistent, and the full-year profit appears concentrated: in fiscal Q2 2026, the quarter ended 2025-12-31, net income was $6.9M, while in fiscal Q3 2026, the quarter ended 2026-03-31, the company lost $488,942. I need to know whether that Q2 gain is recurring or a one-time event. The cash flow picture is sobering: trailing free cash flow was -$4.8M, a -56.2% FCF yield on the $8.5M market cap. FairStock calculations show Piotroski F-Score 0/9 and ROCE -21.50%, even though ROE is 71.33%. At the 2026-10-13 close of $5.16, FairStock calculations show P/B 0.77, P/E 1.29, Graham Number $24.48, margin of safety 78.92%, and PEG 0.02. That looks statistically cheap, but cheapness built on one-time profit and negative cash generation is not the margin of safety Graham meant. The balance sheet has low leverage, D/E 0.08, and Altman Z-Score 2.84. Still, without a real revenue base or proven competitive moat, this is a speculative turnaround, not a proven compounder.

In plain English: Advanced Biomed is a small Taiwan-based company that makes lab-chip tools for cancer detection. It lost money in prior years but reported a profit in the latest fiscal year, mostly from one quarter, while bringing in very little revenue and burning cash. The stock price looks cheap compared with those reported earnings and asset value, but the business has not yet shown a strong, repeatable operating base.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer